Published in final edited form as:

Curr Osteoporos Rep. 2012 September ; 10(3): 208–216. doi:10.1007/s11914-012-0106-3.

Body Composition and Skeletal Health: Too Heavy? Too Thin?

Alexander Faje and Anne Klibanski

Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Abstract

The relationship between body composition and skeletal metabolism has received growing recognition. Low body weight is an established risk factor for fracture. The effect of obesity on skeletal health is less well defined. Extensive studies in patients with anorexia nervosa and obesity have illuminated many of the underlying biologic mechanisms by which body composition modulates bone mass. This review examines the relationship between body composition and bone mass through data from recent research studies throughout the weight spectrum ranging from anorexia nervosa to obesity.

Keywords

Obesity; Anorexia nervosa; Osteoporosis; Bone density; Growth hormone; IGF-1; Estrogen; Adipokines; Body composition; Skeletal health

Introduction

Osteoporosis is characterized by an increased risk of fracture resulting from reduced bone mass and abnormal microarchitectural parameters compared to a normal cohort. The economic burden of skeletal fractures is considerable. Worldwide, 9 million osteoporotic fractures are estimated to have occurred in 2000, and these events represented approximately 0.83% of the global noncommunicable disease burden (5.8 million disability-adjusted life years). The disease burden associated with osteoporotic fractures in Europe exceeded that associated with virtually all common cancers [1].

Health care expenditures attributed to osteoporotic fractures in the United States for adults aged 45 years and over were an estimated \$19 billion in 2005 and are projected to be \$25.3 billion in 2025 [2].

Although the prevalence of osteoporosis is higher in older age groups, fractures remain a significant health burden in younger populations. Approximately 25% of children are injured on an annual basis [3, 4], and fractures account for a quarter of these events [5]. Up to half of children experience at least one fracture by the age of 18 years [6].

Pathologic deviations from a normal body weight are increasingly prevalent. The World Health Organization estimates that global obesity has increased more than twofold over the

Corresponding author: Anne Klibanski, MD, BUL 457, Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA, aklibanski@partners.org.

Alexander Faje, MD, BUL 457, Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA, afaje@partners.org

Disclosure

No potential conflicts of interest relevant to this article were reported.

past 30 years. According to the 2009–2010 National Health and Nutrition Examination Survey, the prevalence of obesity among US adults was 35% [7]. Worrisome rates of obesity have also been observed in children. Ten percent of children ages 5 to 17 years of age are estimated to be overweight [8]. At the opposite end of the weight spectrum, anorexia nervosa (AN), a frequent cause of low weight in developed nations, affects approximately 0.3% of young females and is among the most common chronic illness in this population. The incidence and prevalence of AN appear to be increasing [9].

A majority of individuals with AN have significantly decreased bone mineral density (BMD) [10] and an increased risk of fracture [11, 12]. Traditionally, obesity has been regarded as a protective factor for bone, although recent studies have shown the importance of fat depots at specific sites in determining this effect. The relationship between body composition and bone metabolism has been the subject of intensive research, and recent investigations have explored the complex links between bone, adipose tissue, muscle, the nervous system, neuroendocrine axes, and the gastrointestinal system. Elucidation of the pathways for communication between these systems has enhanced our understanding of skeletal regulation and helped identify new potential biologic targets for therapeutic intervention. In this review, we discuss these relationships in the context of altered body composition and their impact on bone health.

Bone Strength, Fracture Risk, and Body Composition

The assessment of an individual's fracture risk is a complex evaluation that incorporates bone quality and strength, the degree of mechanical strain applied to bone, and the likelihood or frequency of these events. Although higher body weight produces a greater momentum during a fall, fat mass can cushion the area of impact and significantly decrease the effective forces applied to underlying bone. In a study of postmenopausal women, assessment of trochanteric soft tissue thickness reduced estimates of fall forces by as much as 50% at the hip, and incorporation of this parameter alongside areal BMD may better predict fracture risk [13, 14]. In regard to fat depots, both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) contribute to total body mass, but SAT may attenuate bone impact forces in a site-specific manner.

Obese individuals may be at higher risk for fall-related bone injuries. A large adult dataset from the Medical Expenditure Panel Survey suggested that the incidence of fall injuries is higher in obese individuals compared to the normal weight population [15]. Obesity-associated pathologies such as diabetes mellitus and various arthropathic conditions may partially explain an increased risk of fall. More fundamentally, it appears that obese individuals, similar to the elderly, require greater attentional resources to maintain postural stability [16].

Low body weight is a well-known risk factor for fracture and is incorporated into the FRAX and Garvan algorithms, calculations aimed to predict an individual's prospective fracture risk [17]. Studies in adolescents and adults with AN have consistently shown reduced bone mass and an increased fracture incidence and prevalence [10–12, 18–21]. Studies investigating the relationship between bone structure parameters and obesity have produced conflicting results, and a comprehensive discussion of those studies is beyond the scope of this review. The interpretation and comparison of the studies' results can be complicated by lack of group homogeneity (in regard to gender, age, ethnicity, and metabolic profile) and variations in bone measurement technique (eg, dual-energy x-ray absorptiometry [DXA] and peripheral quantitative computed tomography [pQCT]), bone site, and method of analysis (including bone mineral content [BMC]; areal BMD, volumetric BMD, microarchitecture, and algorithm-based analyses such as the Hip Structure Analysis program). Studies have

also utilized varied measures to assess adiposity. These strategies include indirect methods such as body mass index (BMI) and waist circumference or direct measurement by DXA, CT, or magnetic resonance imaging. The presence of multiple compartments of adipose tissue such as SAT, VAT, and bone marrow fat and their potential distinct metabolic characteristics add to the complexity of analysis. Limitations imposed on statistical models by colinearity between highly related variables have not routinely been addressed in a consistent manner in studies seeking to isolate the impact of fat mass on BMD and bone structure. Misleading data and potentially erroneous conclusions can result from treating highly related covariates as independent variables [22•, 23]. The cross-sectional nature of many bone imaging studies is an additional limitation. Recent large longitudinal fracture studies in postmenopausal women suggest that the relationship between obesity and fracture is site-dependent [24•, 25]. Similar results were observed in a recent near-nationwide medical record review in Spain [26]. Comparatively large longitudinal studies are not available in pediatric populations.

Mechanical Stimuli

Mechanical stimuli linked to body weight have been thought to underlie differences in bone mass and fracture risk in patients. The hypothesis that bone adapts to mechanical forces was first postulated by J. Wolff in 1869 and later refined into the “mechanostat” proposal by H. Frost [27]. Experiments have demonstrated that dynamic, rather than static, loads promote bone formation [28, 29], and that the response of bone is governed by the amplitude and frequency of these stimuli [29, 30]. Body mass and composition influence the amplitude of mechanical forces exerted on bone, and the frequency of forces is defined by an individual’s physical activity. Adipose tissue predominantly applies a static load on bone (although it can also indirectly affect the amplitude of dynamic forces). Muscle use creates dynamic strains on bone, and these forces greatly exceed the static gravitational loads resulting from body mass [31, 32].

Because individuals with AN have reduced amounts of lean and fat mass, their skeleton encounters diminished mechanical stimuli. Moreover, exercise does not appear to benefit BMD in individuals with active AN [33]. Obese individuals have excess fat mass and generally also have an increased amount of lean mass. From a biomechanical viewpoint, the excess mass associated with obesity should benefit bone strength, although perhaps less than initial expectations due to the fact that excess fat mass primarily exerts static loads on bone.

Nutrition and Diet

Adequate micronutrient intake, especially calcium and vitamin D, are important factors to maintain normal BMD and prevent fractures. Studies in adults with AN suggest that a significant portion do not meet the recommended intake levels of calcium and vitamin D, although the percentages were comparable to healthy controls [34, 35]. Interestingly, data in adolescent girls showed that those with AN had significantly higher intake of calcium and vitamin D compared to healthy controls, often through the use of dietary supplements, and that a higher percentage of girls with AN met the Dietary Reference Intake for these nutrients [36].

Obesity is often described as a high-caloric state of malnutrition. Micronutrient deficiencies, including vitamin D, are prevalent in obese populations [37, 38]. Studies show an inverse correlation between serum levels of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D and BMI [39, 40]. Proposed etiologies for this correlation have included poor dietary intake, limited sun exposure, decreased hepatic production of 25-hydroxyvitamin D, or reduced bioavailability due to storage in adipose tissue. A study by Wortsman et al. [41] showed decreased serum 25-hydroxyvitamin D levels in obese subjects and concluded that obese

subjects had decreased bioavailability of vitamin D from cutaneous and dietary sources, possibly due to deposition in adipose tissue. Parathyroid hormone (PTH) levels are also elevated in obese populations, and PTH appears to positively correlate with BMI [40, 42]. Although relative vitamin D deficiency is likely contributive, a recent study utilizing citrate-calcium clamps revealed that the PTH-calcium set point is altered in obese subjects. Specifically, the results were consistent with enhanced PTH production in obese individuals [43].

Neuroendocrine Function

Hypothalamic-Pituitary-Gonadal Axis

Reproductive function is typically impaired in extreme states of over- and undernutrition, and amenorrhea is a part of the current *Diagnostic and Statistical Manual of Mental Disorders-IVR* (fourth edition, text revision) diagnostic criteria for AN. Amenorrhea associated with AN is hypothalamic in origin due to impaired gonadotropin-releasing hormone (GnRH) pulsatility and reflects an adaptive response to a negative energy state. In individuals with AN, levels of gonadal steroids are reduced, and gonadotropin secretion patterns mimic those observed in prepubertal or early pubertal children [44, 45]. Administration of exogenous GnRH is able to restore gonadal axis function [46].

Lumbar BMD is lower in adults with the onset of AN during adolescence compared to adult onset and reflects the impact of the disease on attainment of peak bone mass [47]. Bone mass is lower in amenorrheic women with AN compared to eumenorrheic women with comparable body mass [48]. Women have elevated markers of bone resorption after menopause, a physiologic state of hypoestrogenism. A similar pattern of enhanced bone resorption is observed in women with AN [49]. However, oral estrogen administration does not improve BMD in adults with AN [50, 51]. A recent study by our group has demonstrated improvement in BMD in adolescent girls after treatment with physiologic transdermal estradiol [52••]. The dissimilar outcomes may be the consequence of the effects of oral versus transdermal estradiol on levels of insulin-like growth factor 1 (IGF-1) [53], and/or age-dependent skeletal responses to estrogen in undernutrition.

GH-IGF-1 Axis

Impairment of the growth hormone–insulin-like growth factor type 1 (GH-IGF-1) axis can be seen in both under- and overnutrition. Although the mechanisms of impairment differ, a relative state of decreased GH action may be present at both extremes. The anabolic effects of IGF-1 on bone have been well described [54]. Typically, serum levels of IGF-1 are reduced, and levels of GH are elevated in AN, consistent with a state of acquired GH resistance [55, 56]. In adults with AN randomized to placebo or supraphysiologic doses of recombinant human GH, GH did not significantly increase levels of IGF-1, implying a resistance of GH at the level of the liver [57•].

Serum levels of bone formation markers are reduced in AN [44,49], consistent with the loss of an endogenous anabolic factor, and levels of IGF-1 correlate with bone microarchitectural parameters [58]. Administration of recombinant human IGF-1 (rhIGF-1) increases serum markers of bone formation in adolescents and adults with AN [49, 59], and treatment with the combination of an oral contraceptive and rhIGF-1 significantly improves BMD in adult women with AN compared to placebo [52••]. Levels of IGF-1 peak during adolescence and decline with age [60]. The relative contribution of IGF-1 with regard to bone formation is likely to be most profound during adolescence.

Visceral adiposity is associated with reduced GH secretion, and IGF-1 may be lower [61–63]. Hypoactivation of the somatotrophic axis appears limited to individuals with increased

visceral fat [64]. Levels of IGF-1 positively correlate with markers of bone formation and BMD in obese premenopausal women and inversely correlate with visceral adiposity [65].

HPA Axis

Hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis and enhanced cortisol secretion are observed in AN. Serum and urinary measures of cortisol are elevated compared to healthy weight controls, and pooled serum cortisol levels inversely correlate with BMD [66–68]. Excess cortisol has well-defined direct deleterious effects on bone mass and may indirectly influence bone via effects on sex steroids, GH, muscle mass, intestinal calcium absorption, and renal tubular calcium excretion [69–72].

Visceral Fat and Subcutaneous Fat

VAT and SAT compartments may exert distinct effects on bone. VAT is generally considered to be metabolically unhealthy; compared to SAT, VAT exhibits increased immune cell infiltration and a more proinflammatory cytokine/adipokine profile. VAT secretes lower levels of adiponectin and higher levels of proinflammatory cytokines such as interleukin-6 and tumor necrosis factor- α , which stimulate osteoclastogenesis and bone resorption [73]. Higher levels of preadipocyte factor 1 (Pref-1) may promote the development of a proinflammatory environment [74]. Levels of Pref-1 are elevated in the VAT and SAT of metabolically unhealthy obese individuals compared to healthy obese adults and correlate with parameters of metabolic dysfunction [75]. Furthermore, VAT inversely correlates with serum levels of IGF-1 in obese women [76] and is a negative predictor of insulin sensitivity [74].

In a study of obese women, VAT (but not SAT) correlated with marrow adiposity, and marrow fat content inversely correlated with lumbar trabecular BMD [77]. Similar results were observed in a study of normal weight women [78]. Several studies have shown inverse correlations of VAT, but not SAT, with measurements of bone structure and strength [76, 79–81]. Skeletal muscle adipose tissue accumulation is considered pathogenic and shares similar metabolic characteristics with VAT. A large study in girls showed an inverse association of skeletal muscle fat with volumetric BMD and bone strength indices [82]. Similar results were observed in men [83]. Therefore, consideration of the effects on adipose tissue on BMD is likely dependent on specific fat depots.

Adipokines

Leptin is a fat-derived hormone, primarily made in subcutaneous fat, whose concentration is proportional to total body fat mass. Serum levels of leptin are reduced in conditions of low weight, such as AN [84, 85], and are elevated in obesity [86]. Leptin-deficient mice have reduced total bone mass, but the effects of leptin vary according to the bone site examined. Leptin deficiency in mice results in greater BMD in the axial skeleton but reduced values at appendicular locations [87, 88], and its effects are mediated through central and peripheral pathways [89–92]. In patients with the rare condition of congenital leptin deficiency, BMD and BMC appear largely normal, and treatment with leptin did not affect BMD in most of these individuals [93, 94]. Studies examining the relationship between serum leptin levels and BMD in humans have been inconsistent likely due to differences in bone sites examined, gender, and leptin resistance. A recent meta-analysis of studies in nonobese adults indicated that leptin is positively associated with BMD in men and women, especially in postmenopausal women [95]. Serum leptin levels also predict bone microarchitectural parameters in women with AN [58]. In addition to its central and peripheral actions, leptin may influence bone metabolism by its effects on the gonadal, GH, and HPA axes and glucose metabolism/insulin sensitivity [85, 96–98].

Although adiponectin is produced by adipocytes, serum levels inversely correlate with BMI and visceral fat [99, 100]. Studies have shown high, normal, or low levels in patients with AN [101–103], and one study showed an inverse association between adiponectin values and bone density parameters in adolescents with AN [104]. Adiponectin levels are inversely associated with BMD in children and adults [95, 100, 105, 106]. Adiponectin receptors are expressed on osteoblasts and osteoclasts [107, 108]. In vitro experiments with human cell cultures demonstrate that adiponectin promotes osteoclastogenesis through osteoblast production of receptor activator of nuclear factor- κ B ligand (RANKL) and inhibition of osteoprotegerin [109]. Other studies suggest that adiponectin enhances osteoblast proliferation and activity and suppresses osteoclast function [110–112]. Low adiponectin levels are predictive of greater insulin resistance [113]. Other adipokines, including visfatin, resistin, and Dickkopf-1, interact with bone but are outside of the scope of this paper [114–116].

Gut-Derived Hormones and Neuropeptides

The gastrointestinal system secretes a variety of factors that participate in appetite regulation and the maintenance of energy homeostasis in conjunction with the nervous system. Several of these factors have direct effects on bone mass or may impact bone metabolism by their interaction with hormones thus far discussed.

Peptide YY (PYY) is an anorexigenic hormone principally secreted by intestinal endocrine cells, and two forms predominate in the circulation: PYY₁₋₃₆ and PYY₃₋₃₆ [117, 118]. Serum levels of PYY are elevated in AN compared to lean or obese groups [119, 120], and mean overnight PYY levels in women with AN inversely correlate with BMD at multiple sites [121]. PYY and neuropeptide Y (NPY) bind to Y2 receptors with an approximately equal affinity, and PYY₃₋₃₆ is a selective agonist of the Y2 receptor [117]. Central activation of Y2 receptors appears to inhibit osteoblast activity, and hypothalamus-specific adult-onset Y2 receptor deletion in mice results in an anabolic bone phenotype [122]. PYY also displays significant affinity for Y1 receptors, and deletion of Y1 receptors in bone marrow stromal cells enhances osteoblast proliferation and activity [117, 123]. Studies in rodents suggest that PYY may regulate the gonadal axis [124, 125].

Ghrelin is an orexigenic peptide secreted by the stomach and is a potent GH secretagogue [126]. Levels of ghrelin are elevated in AN and are reduced in obesity [127, 128]. Ghrelin levels predict BMD parameters in healthy girls and elderly men [129, 130]. In vitro experiments in rats demonstrate that ghrelin stimulates osteoblast proliferation [131]. Like PYY, ghrelin modulates the gonadal axis. In rat models, ghrelin regulates the gonadal axis at the level of the hypothalamus and pituitary, and ghrelin administration to men suppresses luteinizing hormone secretion [132, 133]. Additionally, ghrelin influences β -cell survival, insulin secretion, and insulin sensitivity [134].

Insulin integrates effects of many of the hormones thus far discussed. In rodents insulin exerts anabolic effects on bone in vivo [135, 136]. Insulin stimulates osteoblasts directly and may participate in a regulatory loop between the bone and pancreas in conjunction with osteocalcin [137, 138]. Serum insulin levels are often elevated in obese individuals and are reduced in girls with AN compared to healthy controls. Insulin levels correlate with markers of bone turnover in AN and predicts BMD in elderly men and women [139, 140]. Consistent with these findings, patients with type 1 diabetes, a state of insulin deficiency, have an increased risk of fracture [141].

NPY is emerging as a significant intermediary between fat, bone, and the nervous system. NPY is an orexigenic hormone produced in the central and peripheral nervous system, with particularly high expression in the hypothalamus [142, 143]. Recent studies have also shown

that NPY is expressed by subcutaneous and visceral fat in rodents and humans and by osteocytes and osteoblasts in mice [144–147]. Peripherally, NPY receptors are expressed on mesenchymal stem cells (MSCs), osteoblasts, preadipocytes, and adipocytes in mice [123, 144, 147]. Current evidence suggests that NPY acts centrally in the hypothalamus and peripherally to inhibit osteoblast activity. Central and peripheral NPY also promote lipogenesis [148]. In a small study, serum levels of NPY were increased in women with AN compared to healthy controls [149]. In a study of lean, overweight, and obese adults, serum NPY correlated positively with BMI, although this association appeared to be present only among hypertensive subjects [150].

Bone Marrow Adiposity

The regulation of bone marrow MSC differentiation has been the focus of extensive research. Osteoblasts and marrow adipocytes differentiate from MSCs [151]. Regulation of MSC differentiation into these lineages may influence bone formation [152]. Studies have demonstrated an inverse correlation between marrow fat content and BMD in adolescents and adults and linked age-related bone loss to increased marrow adiposity [153–157]. Higher marrow fat content has also been observed in prolonged immobilization and women with AN [158, 159]. Hormones implicated in the regulation of MSC differentiation include estrogen, IGF-1, and glucocorticoids [160–162]. More recently, Pref-1 has been shown to inhibit adipocyte and osteoblast differentiation [163–165]. Serum levels of Pref-1 are elevated in women with AN compared to healthy controls, and levels of Pref-1 correlated positively with bone marrow fat content and inversely with BMD [166]. The role of bone marrow adiposity as a factor in bone mass regulation is under active investigation.

Conclusions

Body composition influences bone directly via mechanical stimuli and adipokine secretion and more obliquely through the communication with and modulation of various central and peripheral pathways. The metabolic characteristics of adipose tissue are not uniform, and different depots may exert distinct effects on the regulation of bone mass and structure. The effect of body composition on clinical outcomes, namely fracture risk, integrates the metabolic effects of energy balance, lean mass, and adipose tissue mass on bone and the frequency and severity of mechanical “challenges” that the skeleton encounters. Enhanced understanding of the pathways that govern skeletal metabolism will support the identification of therapeutic strategies to maximize skeletal strength.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006; 17:1726–1733. [PubMed: 16983459]
2. National Osteoporosis Foundation. [Accessed March 2012] Fast Facts. Available at <http://www.nof.org/node/40>
3. Scheidt PC, Harel Y, Trumble AC, et al. The epidemiology of nonfatal injuries among US children and youth. *Am J Public Health*. 1995; 85:932–938. [PubMed: 7604916]
4. Walsh SS, Jarvis SN, Towner EM, Aynsley-Green A. Annual incidence of unintentional injury among 54,000 children. *Inj Prev*. 1996; 2:16–20. [PubMed: 9346048]

5. Landin LA. Epidemiology of children's fractures. *J Pediatr Orthop B*. 1997; 6:79–83. [PubMed: 9165435]
6. Jones IE, Williams SM, Dow N, Goulding A. How many children remain fracture-free during growth? A longitudinal study of children and adolescents participating in the Dunedin multidisciplinary health and development study. *Osteoporos Int*. 2002; 13:990–995. [PubMed: 12459942]
7. Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. *Int J Eat Disord*. 2003; 34:383–396. [PubMed: 14566926]
8. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA*. 2012; 307:491–497. [PubMed: 22253363]
9. Lobstein T, Baur L, Uauy R. International Obesity Task Force. Obesity in children and young people: a crisis in public health. *Obesity Rev*. 2004; 5:4–104.
10. Miller KK, Grinspoon SK, Ciampa J, et al. Medical findings in outpatients with anorexia nervosa. *Arch Intern Med*. 2005; 165:561–566. [PubMed: 15767533]
11. Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa: a longitudinal study of cortical bone mass. *JAMA*. 1991; 265:1133–1138. [PubMed: 1995999]
12. Lucas AR, Melton LJ 3rd, Crowson CS, O'Fallon WM. Long-term fracture risk among women with anorexia nervosa: a population based cohort study. *Mayo Clin Proc*. 1999; 74:972–977. [PubMed: 10918862]
13. Bouxsein ML, Szulc P, Munoz F, et al. Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. *J Bone Miner Res*. 2007; 22:825–831. [PubMed: 17352651]
14. Roberts BJ, Thrall E, Muller JA, Bouxsein ML. Comparison of hip fracture risk prediction by femoral aBMD to experimentally measured factor of risk. *Bone*. 2010; 46:742–746. [PubMed: 19854307]
15. Finkelstein EA, Chen H, Prabhu M, et al. The relationship between obesity and injuries among U.S. adults. *Am J Health Promot*. 2007; 21:460–468. [PubMed: 17515011]
16. Mignardot JB, Olivier I, Promayon E, Nougier V. Obesity impact on the attentional cost for controlling posture. *PLoS One*. 2010; 5:e14387. [PubMed: 21187914]
17. van Geel TA, van den Bergh JP, Dinant GJ, Geusens PP. Individualizing fracture risk prediction. *Maturitas*. 2010; 65:143–148. [PubMed: 20053513]
18. Soyka L, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2002; 87:4177–4185. [PubMed: 12213868]
19. Bachrach LK, Guido D, Katzman D, et al. Decreased bone density in adolescent girls with anorexia nervosa. *Pediatrics*. 1990; 86:440–447. [PubMed: 2388792]
20. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. *Ann Intern Med*. 2000; 133:790–794. [PubMed: 11085841]
21. Vestergaard P, Emborg C, Støving RK, et al. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study. *Int J Eat Disord*. 2002; 32:301–308. [PubMed: 12210644]
22. Reid IR. Fat and bone. *Arch Biochem Biophys*. 2010; 503:20–27. In this review the author illustrates an excellent example of the statistical consequences of inappropriately treating highly collinear variables as independent factors. Some papers' methods to adjust fat mass for body size lack adequate statistical rigor and may yield erroneous conclusions. [PubMed: 20599663]
23. Wells JC, Cole TJ. ALSPAC study steam: Adjustment of fat-free mass and fat mass for height in children aged 8 y. *Int J Obes Relat Metab Disord*. 2002; 26:947–952. [PubMed: 12080448]
24. Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. *AM J Med*. 2011; 124:1043–1050. This is a large longitudinal study that demonstrates site specificity in regard to fracture risk in an obese population. [PubMed: 22017783]
25. Beck TJ, Petit MA, Wu G, et al. Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. *J Bone Miner Res*. 2009; 24:1369–1379. [PubMed: 19292617]

26. Prieto-Alhambra D, Premaor MO, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. *J Bone Miner Res*. 2011 Epub.
27. Frost HM. Bone “mass” and the “mechanostat”: A proposal. *Anat Rec*. 1987; 219:1–9. [PubMed: 3688455]
28. Liskova M, Hert J. Reaction of bone to mechanical stimuli. Part 2. Periosteal and endosteal reaction to tibial diaphysis in rabbit to intermittent loading. *Folia Morphol*. 1971; 19:301–317.
29. Lanyon LE, Rubin CT. Static vs dynamic loads as an influence on bone remodeling. *J Biomech*. 1984; 17:897–905. [PubMed: 6520138]
30. Rubin CT, McLeod KJ. Promotion of bony ingrowth by frequency-specific, low-amplitude mechanical strain. *Clin Orthop Rel Res*. 1994; 298:165–174.
31. Pauwels, F. *Gesammelte Abhandlungen zur Funktionellen Anatomie des Bewegungsapparates*. Springer; Berlin: 1965.
32. Lu TW, O’Conner JJ, Taylor SJG, Walker PS. Influence of muscle activity on the forces in the femur: Comparison between in vivo measurement and calculation. *Trans Orthop Res Soc*. 1997; 22:721.
33. Waugh EJ, Woodside DB, Beaton DE, et al. Effects of exercise on bone mass in young women with anorexia nervosa. *Med Sci Sports Exerc*. 2011; 43:755–763. [PubMed: 20962688]
34. Beaumont P, Chambers T, Rouse L, Abraham S. The diet composition and nutritional knowledge of patients with anorexia nervosa. *J Hum Nutr*. 1981; 35:265–273. [PubMed: 7276554]
35. Hadigan CM, Anderson EJ, Miller KK, et al. Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. *Int J Eat Disord*. 2000; 28:284–292. [PubMed: 10942914]
36. Misra M, Tsai P, Anderson EJ, et al. Nutrient intake in community-dwelling adolescent girls with anorexia nervosa and in healthy adolescents. *Am J Clin Nutr*. 2006; 84:698–706. [PubMed: 17023694]
37. Ernst B, Thurnheer M, Schmid SM, Schultes B. Evidence for the necessity to systematically assess micronutrient status prior to bariatric surgery. *Obes Surg*. 2009; 19:66–73. [PubMed: 18491197]
38. Strohmayer E, Via MA, Yanagisawa R. Metabolic management following bariatric surgery. *Mt Sinai J Med*. 2010; 77:431–445. [PubMed: 20960547]
39. Konradsen S, Ag H, Lindberg F, et al. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. *Eur J Nutr*. 2008; 47:87–91. [PubMed: 18320256]
40. Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. *J Clin Endocrinol Metab*. 2004; 89:1196–1199. [PubMed: 15001609]
41. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr*. 2000; 72:690–693. [PubMed: 10966885]
42. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. *Eur J Endocrinol*. 2004; 151:167–172. [PubMed: 15296470]
43. Hultin H, Edfeldt K, Sundbom M, Hellman P. Left-shifted relation between calcium and parathyroid hormone in obesity. *J Clin Endocrinol Metab*. 2010; 95:3973–3981. [PubMed: 20519351]
44. Soyka LA, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2002; 87:4177–4185. [PubMed: 12213868]
45. Boyar RM, Katz J, Finkelstein JW, et al. Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. *N Engl J Med*. 1974; 291:861–865. [PubMed: 4412035]
46. Giusti M, Torre R, Traverso L, et al. Endogenous opioid blockade and gonadotropin secretion: role of pulsatile luteinizing hormone-releasing hormone administration in anorexia nervosa and weight loss amenorrhea. *Fertil Steril*. 1988; 49:797–801. [PubMed: 3129313]
47. Biller BM, Saxe V, Herzog DB, et al. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. *J Clin Endocrinol Metab*. 1989; 68:548–554. [PubMed: 2493036]
48. Miller KK, Grinspoon S, Gleysteen S, et al. Preservation of neuroendocrine control of reproductive function despite severe undernutrition. *J Clin Endocrinol Metab*. 2004; 89:4434–4438. [PubMed: 15356043]

49. Grinspoon S, Baum H, Lee K, et al. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. *J Clin Endocrinol Metab.* 1996; 81:3864–3870. [PubMed: 8923830]
50. Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. *J Clin Endocrinol Metab.* 1995; 80:898–904. [PubMed: 7883849]
51. Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. *J Clin Endocrinol Metab.* 2002; 87:2883–2891. [PubMed: 12050268]
52. Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. *J Bone Miner Res.* 2011; 26:2430–2438. Treatment with physiologic estradiol restored normal bone accrual in adolescent girls with AN. [PubMed: 21698665]
53. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. *J Clin Endocrinol Metab.* 1991; 72:374–381. [PubMed: 1991807]
54. Canalis E, Giustina A, Bilezikian JP. Mechanisms of Anabolic Therapies for Osteoporosis. *N Engl J Med.* 2007; 357:905–916. [PubMed: 17761594]
55. Scacchi M, Pincelli AI, Caumo A, et al. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. *J Clin Endocrinol Metab.* 1997; 82:3225–3229. [PubMed: 9329343]
56. Misra M, Miller K, Bjornson J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. *J Clin Endocrinol Metab.* 2003; 88:5615–5623. [PubMed: 14671143]
57. Fazeli PK, Lawson EA, Prabhakaran R, et al. Effects of recombinant human growth hormone in anorexia: a randomized, placebo-controlled study. *J Clin Endocrinol Metab.* 2010; 95:4889–4897. This study demonstrates the presence of GH resistance in AN as the basis for relative IGF-1 deficiency. [PubMed: 20668047]
58. Lawson EA, Miller KK, Bredella MA, et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. *Bone.* 2010; 46:458–463. [PubMed: 19747572]
59. Misra M, McGrane J, Miller KK, et al. Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. *Bone.* 2009; 45:493–498. [PubMed: 19523548]
60. Brabant G, von zur Mühlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. *Horm Res.* 2003; 60:53–60. [PubMed: 12876414]
61. Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. *J Clin Endocrinol Metab.* 2008; 93:2507–2514. [PubMed: 18445664]
62. Rasmussen MH, Hvidberg A, Juul A, et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-1 levels in obese subjects. *J Clin Endocrinol Metab.* 80:1407–1415. [PubMed: 7536210]
63. Brick DJ, Gerweck AV, Meenaghan E, et al. Miller KK. Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity. *Eur J Endocrinol.* 2010; 163:185–191. [PubMed: 20501597]
64. Pijl H, Langendonk JG, Burggraaf J, et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. *J Clin Endocrinol Metab.* 2001; 86:5509–5515. [PubMed: 11701729]
65. Bredella MA, Torriani M, Ghomi RH, et al. Determinants of bone mineral density in obese premenopausal women. *Bone.* 2011; 48:748–754. [PubMed: 21195217]

66. Misra M, Miller KK, Almazan C, et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. *J Clin Endocrinol Metab.* 2004; 89:4972–4980. [PubMed: 15472193]
67. Lawson EA, Donoho D, Miller KK, et al. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. *J Clin Endocrinol Metab.* 2009; 94:4710–4716. [PubMed: 19837921]
68. Misra M, Aggarwal A, Miller KK, et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. *Pediatrics.* 2004; 114:1574–1583. [PubMed: 15574617]
69. Padmanabhan V, Keech C, Convey EM. Cortisol inhibits and adrenocorticotropin has no effect on luteinizing hormone-releasing hormone-induced release of luteinizing hormone from bovine pituitary cells in vitro. *Endocrinology.* 1983; 112:1782–1787. [PubMed: 6299709]
70. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of cortisone treatment on the active transport of calcium by the small intestine. *J Clin Invest.* 1971; 50:1309–1321. [PubMed: 4325312]
71. Feher JJ, Wasserman RH. Intestinal calcium-binding protein and calcium absorption in cortisol-treated chicks: effects of vitamin D3 and 1,25-dihydroxyvitamin D3. *Endocrinology.* 1979; 104:547–551. [PubMed: 221183]
72. Hardy R, Cooper MS. Adrenal gland and bone. *Arch Biochem Biophys.* 2010; 503:137–145. [PubMed: 20542010]
73. Blüher M. Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes.* 2009; 117:241–250. [PubMed: 19358089]
74. Abdallah BM, Boissy P, Qihua T, et al. *dlk1/FA1* regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-inflammatory cytokines and immune response-related factors. *J Biol Chem.* 2007; 282:7339–7351. [PubMed: 17182623]
75. O'Connell J, Lynch L, Hogan A, et al. Preadipocyte factor-1 is associated with metabolic profile in severe obesity. *J Clin Endocrinol.* 2011; 96:E680–684.
76. Bredella MA, Torriani M, Ghomi RH, et al. Determinants of bone mineral density in obese premenopausal women. *Bone.* 2011; 48:748–754. [PubMed: 21195217]
77. Bredella MA, Torriani M, Ghomi RH, et al. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. *Obesity.* 19:49–53. [PubMed: 20467419]
78. Shen W, Chen J, Punyanitya M, et al. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. *Osteoporos Int.* 2007; 18:641–647. [PubMed: 17139464]
79. Afghani A, Goran MI. The interrelationships between abdominal adiposity, leptin and bone mineral content in overweight Latino children. *Horm Res.* 2009; 72:82–87. [PubMed: 19690425]
80. Russell M, Mendes N, Miller KK, et al. Visceral fat is a negative predictor of bone density measures in obese adolescent girls. *J Clin Endocrinol Meta.* 2010; 95:1247–1255.
81. Gilsanz V, Chalfant J, Mo AO, et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. *J Clin Endocrinol Metab.* 2009; 94:3387–3393. [PubMed: 19531595]
82. Farr JN, Funk JL, Chen Z, et al. Skeletal muscle fat content is inversely associated with bone strength in young girls. *J Bone Miner Res.* 2011; 26:2217–2225. [PubMed: 21544865]
83. Yerges-Armstrong LM, Miljkovic I, Cauley JA, et al. Adipose tissue and volumetric bone mineral density of older Afro-Caribbean men. *J Bone Miner Res.* 2010; 25:2221–2228. [PubMed: 20499353]
84. Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. *J Clin Endocrinol Metab.* 1996; 81:3861–3863. [PubMed: 8923829]
85. Misra M, Miller KK, Kuo K, et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. *Am J Physiol Endocrinol Metab.* 2005; 289:E373–381. [PubMed: 15811876]
86. Sinha MK, Ohannesian JP, Heiman ML, et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest.* 1996; 97:1344–1347. [PubMed: 8636448]

87. Cornish J, Callon K, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. *J Endocrinol.* 2002; 175:405–415. [PubMed: 12429038]
88. Hamrick M, Pennington C, Newton D, et al. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. *Bone.* 2004; 34:376–383. [PubMed: 15003785]
89. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell.* 2000; 100:197–207. [PubMed: 10660043]
90. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. *J Cell Biochem.* 2002; 85:825–836. [PubMed: 11968022]
91. Hamrick MW, Della-Fera MA, Choi YH, et al. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. *J Bone Miner Res.* 2005; 20:994–1001. [PubMed: 15883640]
92. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. *J Bone Miner Res.* 2002; 17:200–209. [PubMed: 11811550]
93. Paz-Filho G, Mastronardi C, Delibasi T, et al. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. *Arq Bras Endocrinol Metabol.* 2010; 54:690–697. [PubMed: 21340154]
94. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *J Clin Invest.* 2002; 110:1093–1103. [PubMed: 12393845]
95. Biver E, Salliot C, Combescure C, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2011; 96:2703–2713. [PubMed: 21778223]
96. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. *N Engl J Med.* 2004; 351:987–997. [PubMed: 15342807]
97. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. *Proc Natl Acad Sci USA.* 2011; 108:6585–6590. [PubMed: 21464293]
98. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. *Am J Physiol Endocrinol Metab.* 2011; 301:E567–584. [PubMed: 21791620]
99. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun.* 1999; 257:79–83. [PubMed: 10092513]
100. Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. *Bone.* 2003; 33:646–651. [PubMed: 14555270]
101. Misra M, Miller KK, Kuo K, et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. *Am J Physiol Endocrinol Metab.* 2005; 289:E373–E381. [PubMed: 15811876]
102. Pannacciulli N, Vettor R, Milan G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. *J Clin Endocrinol Metab.* 2003; 88:1748–1752. [PubMed: 12679468]
103. Tagami T, Satoh N, Usui T, et al. Adiponectin in anorexia nervosa and bulimia nervosa. *J Clin Endocrinol Metab.* 2004; 89:1833–1837. [PubMed: 15070952]
104. Sayers A, Timpson NJ, Sattar N, et al. Adiponectin and its association with bone mass accrual in childhood. *J Bone Miner Res.* 2010; 25:2212–2220. [PubMed: 20499348]
105. Richards JB, Valdes AM, Burling K, et al. Serum adiponectin and bone mineral density in women. *J Clin Endocrinol Metab.* 2007; 92:1517–1523. [PubMed: 17264180]
106. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. *J Cell Biochem.* 2006; 99:196–208. [PubMed: 16598753]
107. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. *Bone.* 2004; 35:842–849. [PubMed: 15454091]
108. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. *J Bone Miner Res.* 2006; 21:1648–1656. [PubMed: 16995820]

109. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. *Exp Cell Res.* 2005; 309:99–109. [PubMed: 15963981]
110. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. *Biochem Biophys Res Commun.* 2005; 331:520–526. [PubMed: 15850790]
111. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. *J Cell Biochem.* 2006; 99:196–208. [PubMed: 16598753]
112. Cambuli VM, Musiu MC, Incani M, et al. Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. *J Clin Endocrinol Metab.* 2008; 93:3051–3057. [PubMed: 18492759]
113. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. *J Clin Endocrinol Metab.* 2007; 92:2046–2052. [PubMed: 17356044]
114. Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. *Calcif Tissue Int.* 2007; 80:201–210. [PubMed: 17340225]
115. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. *J Cell Biochem.* 2006; 99:824–834. [PubMed: 16721825]
116. Dimitri P, Wales JK, Bishop N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signaling resulting in reduced bone mass. *Bone.* 2011; 48:189–196. [PubMed: 20932948]
117. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. *Pharmacol Rev.* 1998; 50:143–150. [PubMed: 9549761]
118. Grandt D, Schimiczek M, Beglinger C, et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. *Regul Pept.* 1994; 51:151–159. [PubMed: 8059011]
119. Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab.* 2006; 91:1027–1033. [PubMed: 16278259]
120. Pfluger PT, Kampe J, Castaneda TR, et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. *J Clin Endocrinol Metab.* 2007; 92:583–588. [PubMed: 17119001]
121. Utz AL, Lawson EA, Misra M, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. *Bone.* 2008; 43:135–139. [PubMed: 18486583]
122. Allison SJ, Baldock P, Sainsbury A, et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. *J Biol Chem.* 2006; 281:23436–23444. [PubMed: 16785231]
123. Lee NJ, Doyle KL, Sainsbury A, et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. *J Bone Miner Res.* 2010; 25:1736–1747. [PubMed: 20200977]
124. Fernandez-Fernandez R, Aguilar E, Tena-Sempere M, Pinilla L. Effects of polypeptide YY(3-36) upon luteinizing hormone-releasing hormone and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies. *Endocrinology.* 2005; 146:1403–1410. [PubMed: 15564330]
125. Pinilla L, Fernández-Fernández R, Roa J, et al. Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat. *Am J Physiol Endocrinol Metab.* 2007; 293:E1385–1392. [PubMed: 17785504]
126. Gasco V, Beccuti G, Marotta F, et al. Endocrine and metabolic actions of ghrelin. *Endocr Dev.* 2010; 17:86–95. [PubMed: 19955759]
127. Misra M, Miller KK, Kuo K, et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. *Am J Physiol Endocrinol Metab.* 2005; 289:E347–356. [PubMed: 15755766]

128. Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. *Diabetes*. 2001; 50:707–709. [PubMed: 11289032]
129. Kluge M, Schüssler P, Uhr M, et al. Ghrelin suppresses secretion of luteinizing hormone in humans. *J Clin Endocrinol Metab*. 2007; 92:3202–3205. [PubMed: 17550958]
130. Fernández-Fernández R, Tena-Sempere M, Navarro VM, et al. Effects of ghrelin upon gonadotropin-releasing hormone and gonadotropin secretion in adult female rats: in vivo and in vitro studies. *Neuroendocrinology*. 2005; 82:245–255. [PubMed: 16721030]
131. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. *J Bone Miner Res*. 2005; 20:790–798. [PubMed: 15824852]
132. Misra M, Miller KK, Stewart V, et al. Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. *J Clin Endocrinol Metab*. 2005; 90:5082–5087. [PubMed: 15998770]
133. Gonnelli S, Caffarelli C, Del Santo K, et al. The relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. *Calcif Tissue Int*. 2008; 83:55–60. [PubMed: 18563283]
134. van der Lely AJ. Ghrelin and new metabolic frontiers. *Horm Res*. 2009; 71(Suppl 1):129–133. [PubMed: 19153523]
135. Thrailkill KM, Liu L, Wahl EC, et al. Bone formation is impaired in a model of type 1 diabetes. *Diabetes*. 2005; 54:2875–2881. [PubMed: 16186388]
136. Verhaeghe J, Suiker AM, Visser WJ, et al. The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. *J Endocrinol*. 1992; 134:485–492. [PubMed: 1402554]
137. Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. *Cell*. 2010; 142:309–319. [PubMed: 20655471]
138. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. *Cell Biochem Funct*. 2010; 28:334–341. [PubMed: 20517899]
139. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2007; 92:2046–2052. [PubMed: 17356044]
140. Stolk RP, Van Daele PL, Pols HA, et al. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. *Bone*. 1996; 18:545–549. [PubMed: 8805995]
141. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Am J Epidemiol*. 2007; 166:495–505. [PubMed: 17575306]
142. Bernet F, Dedieu JF, Laborie C, et al. Circulating neuropeptide Y (NPY) and catecholamines in rat under resting and stress conditions. Arguments for extra-adrenal origin of NPY, adrenal and extra-adrenal sources of catecholamines. *Neurosci Lett*. 1998; 250:45–48. [PubMed: 9696062]
143. de Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system--II. Immunohistochemical analysis. *Neuroscience*. 1986; 18:545–618. [PubMed: 3755809]
144. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. *Nat Med*. 2007; 13:803–811. [PubMed: 17603492]
145. Yang K, Guan H, Arany E, et al. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. *FASEB*. 2008; 22:2452–2464.
146. Kos K, Harte AL, James S, et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. *Am J Physiol Endocrinol Metab*. 2007; 293:E1335–E1340. [PubMed: 17785501]
147. Igwe JC, Jiang X, Paic F, et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. *J Cell Biochem*. 2009; 108:621–630. [PubMed: 19670271]
148. Shi YC, Baldock PA. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. *Bone*. 2012; 430–436. [PubMed: 22008645]

149. Sedláková D, Kopecká J, Papežová H, et al. Changes of plasma obestatin, ghrelin and NPY in anorexia and bulimia nervosa patients before and after a high-carbohydrate breakfast. *Physiol Res.* 2011; 60:165–173. [PubMed: 20945961]
150. Baltazi M, Katsiki N, Savopoulos C, et al. Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (α-MSH) levels in patients with or without hypertension and/or obesity: a pilot study. *Am J Cardiovasc Dis.* 2011; 1:48–59. [PubMed: 22254185]
151. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999; 284:143–147. [PubMed: 10102814]
152. Qiu W, Andersen TE, Bollerslev J, et al. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. *J Bone Miner Res.* 2007; 22:1720–1731. [PubMed: 17680723]
153. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adult. *J Clin Endocrinol Metab.* 2008; 93:2281–2286. [PubMed: 18381577]
154. Di Iorgi N, Mo AO, Grimm K, et al. Bone acquisition in healthy young females is reciprocally related to marrow adiposity. *J Clin Endocrinol Metab.* 2010; 95:2977–2982. [PubMed: 20392872]
155. Wren TA, Chung SA, Dorey FJ, et al. Bone marrow fat is inversely related to cortical bone in young and old subjects. *J Clin Endocrinol Metab.* 2011; 96:782–786. [PubMed: 21177790]
156. Verma S, Rajaratnam JH, Denton J, et al. Adipocyte proportion of bone marrow is inversely related to bone formation in osteoporosis. *J Clin Pathol.* 2002; 55:693–698. [PubMed: 12195001]
157. Yeung DK, Griffith JF, Antonio GE, et al. Osteoporosis is associated with increased marrow fat content and decreased marrow fat unsaturation: a proton MR spectroscopy study. *J Magn Reson Imaging.* 2005; 22:279–285. [PubMed: 16028245]
158. Trudel G, Payne M, Madler B, et al. Bone marrow fat accumulation after 60 days of bed rest persisted 1 year after activities were resumed along with hemopoietic stimulation: the Women International Space Simulation for Exploration study. *J Appl Physiol.* 2009; 107:540–548. [PubMed: 19478189]
159. Bredella MA, Fazeli PK, Miller KK, et al. Increased bone marrow fat in anorexia nervosa. *J Clin Endocrinol Metab.* 2009; 94:2129–2136. [PubMed: 19318450]
160. Zhao JW, Gao ZL, Mei H, et al. Differentiation of human mesenchymal stem cells: the potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation. *Am J Med Sci.* 2011; 341:460–468. [PubMed: 21289500]
161. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone-marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. *Cell Mol Life Sci.* 2009; 66:236–253. [PubMed: 18854943]
162. Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. *Trends Endocrinol Metab.* 2006; 17:144–149. [PubMed: 16678739]
163. Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. *Cell.* 1993; 73:725–734. [PubMed: 8500166]
164. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. *Histol Histopathol.* 2000; 15:119–129. [PubMed: 10668203]
165. Wang Y, Sul HS. Pref-1 regulates mesenchymal cell commitment and differentiation through Sox9. *Cell Metabolism.* 2009; 9:287–302. [PubMed: 19254573]
166. Fazeli PK, Bredella MA, Misra M, et al. Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. *J Clin Endocrinol Metab.* 2010; 95:407–413. [PubMed: 19850693]